RE: A very very very Strong buy1 Sep 2025 19:21
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:
"The new patent on P140 is the result of impressive and dedicated research by ImmuPharma Biotech and is truly a game changer for ImmuPharma. The discovery of a new mechanism of action and identification of Type M, a sub-type of auto-immune disorders, greatly expands the scope ofP140 across a wide range of autoimmune diseases and the filing of a patent application directed towards this discovery significantly enhances the business case due to the potential for long-term increased revenues.
This combination makes P140 a unique and extremely valuable asset, particularly with the potential for 20 years of commercial exclusivity, *and will add enormous traction to our current discussions with potential global partners of P140."*